Ocular Therapeutix™ Announces Early Assignment of Permanent and Specific J-Code (J1096) for DEXTENZA® (dexamethasone ophthalmic insert) 0.4mg by the Centers for Medicare and Medicaid Services
BEDFORD, Mass.--(BUSINESS WIRE)--<a href="https://twitter.com/search?q=%24OCUL&src=ctag" target="_blank">$OCUL</a> <a href="https://twitter.com/hashtag/OCUTX?src=hash" target="_blank">#OCUTX</a>--Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that the Centers for Medicare and Medicaid Services (CMS) has assigned a specific and permanent reimbursement J-code, through the Healthcare Common Procedure Coding System (HCPCS) for DEXTENZA® (dexamethasone ophthalmic insert) 0.4mg that is approved fo